http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2010108640-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-138 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-46 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-46 |
| filingDate | 2008-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2011-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2010108640-A |
| titleOfInvention | NEW COMBINATION OF THERAPEUTIC AGENTS |
| abstract | 1. A pharmaceutical product containing! a) the first therapeutic agent, which is a pharmaceutically acceptable anion (endo) -3- (2-cyano-2,2-diphenyl-ethyl) -8,8-dimethyl-8-azonia-bicyclo [3.2.1] octane; and! b) at least one of the following other therapeutic agents selected from the group consisting of salmeterol xinafoate and fluticasone propionate; and where these therapeutic agents are possibly present in enantiomerically pure form or as a racemic mixture. ! 2. The product according to claim 1, where the first therapeutic agent is (endo) -3- (2-cyano-2,2-diphenyl-ethyl) -8,8-dimethyl-8-azonia-bicyclo bromide [3.2.1 ] octane. ! 3. The product according to claim 1 or 2, containing the first therapeutic agent and salmeterol xinafoate. ! 4. The product according to claim 1 or 2, containing the first therapeutic agent and fluticasone propionate. ! 5. The product according to claim 1 or 2, where both agents of salmeterol xinafoate and fluticasone propionate are present. ! 6. The product according to claim 3, where salmeterol xinafoate is present in an amount of 50 μg / dose. ! 7. The product according to claim 5, where salmeterol xinafoate is present in an amount of 50 μg / dose. ! 8. The product according to claim 4, where fluticasone propionate is present in an amount of 250 μg / dose. ! 9. The product according to claim 1, where the first therapeutic agent is present in an amount of from about 10 to 100 μg / dose. ! 10. The product according to claim 1 in a form suitable for administration by oral or nasal administration. ! 11. The product of claim 10, presented in the form of an aerosol composition containing a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane, monofluorotrichloromethane and dichlorodifluoromethane or any mixture of two or more of these compounds and, possibly, |
| priorityDate | 2007-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 35.